Tag Archives: Ryan O’Hare

Gene editing to identify and change parts of chicken DNA and limit the spread of bird flu virus

This news comes from the University of Edinburgh (Scotland). From an October 10, 2023 news item on phys.org, Note: A link has been removed,

Scientists have used gene editing techniques to identify and change parts of chicken DNA that could limit the spread of the bird flu virus in the animals.

Researchers were able to restrict—but not completely block—the virus from infecting chickens by altering a small section of their DNA.

The birds showed no signs that the change in their DNA had any impact on their health or well-being.

The findings are an encouraging step forward, but experts highlight that further gene edits would be needed to produce a chicken population which cannot be infected by bird flu—one of the world’s most costly animal diseases.

An October 10, 2023 University of Edinburgh press release, which originated the news item, provides more detail about this research,

Gene editing

Scientists from University of Edinburgh, Imperial College London and the Pirbright Institute bred the chickens using gene editing techniques to alter the section of DNA responsible for producing the protein ANP32A. During an infection, flu viruses hijack this molecule to help replicate themselves.

When the ANP32A gene-edited chickens were exposed to a normal dose of the H9N2-UDL strain of avian influenza virus – commonly known as bird flu – 9 out of 10 birds remained uninfected and there was no spread to other chickens.

Partial protection

The research team then exposed the gene-edited birds to an artificially high dose of avian influenza virus to further test their resilience.

When exposed to the high dose, half of the group – 5 out of 10 birds – became infected. However, the gene edit did provide some protection, with the amount of virus in the infected gene-edited chickens much lower than the level typically seen during infection in non-gene-edited chickens.

The gene edit also helped to limit onward spread of the virus to just one of four non-gene-edited chickens placed in the same incubator. There was no transmission to gene-edited birds.

Viral evolution

Scientists found that in the ANP32A gene-edited birds, the virus had adapted to enlist the support of two related proteins – ANP32B and ANP32E – to replicate.

Following lab tests, scientists found that some of the mutations enabled the virus to utilise the human version of ANP32, but its replication remained low in cell cultures from the human airway.

Experts say that additional genetic changes would be needed for the virus to infect and spread effectively in humans.

However, the findings demonstrate that the single ANP32A gene edit is not robust enough for application in the production of chickens, according to the team.

Gene editing

Scientists from University of Edinburgh, Imperial College London and the Pirbright Institute bred the chickens using gene editing techniques to alter the section of DNA responsible for producing the protein ANP32A. During an infection, flu viruses hijack this molecule to help replicate themselves.

When the ANP32A gene-edited chickens were exposed to a normal dose of the H9N2-UDL strain of avian influenza virus – commonly known as bird flu – 9 out of 10 birds remained uninfected and there was no spread to other chickens.

Partial protection

The research team then exposed the gene-edited birds to an artificially high dose of avian influenza virus to further test their resilience.

When exposed to the high dose, half of the group – 5 out of 10 birds – became infected. However, the gene edit did provide some protection, with the amount of virus in the infected gene-edited chickens much lower than the level typically seen during infection in non-gene-edited chickens.

The gene edit also helped to limit onward spread of the virus to just one of four non-gene-edited chickens placed in the same incubator. There was no transmission to gene-edited birds.

Viral evolution

Scientists found that in the ANP32A gene-edited birds, the virus had adapted to enlist the support of two related proteins – ANP32B and ANP32E – to replicate.

Following lab tests, scientists found that some of the mutations enabled the virus to utilise the human version of ANP32, but its replication remained low in cell cultures from the human airway.

Experts say that additional genetic changes would be needed for the virus to infect and spread effectively in humans.

However, the findings demonstrate that the single ANP32A gene edit is not robust enough for application in the production of chickens, according to the team.

Further edits

To prevent the emergence of escape viruses – viruses that adapt to evade the gene edit and cause infection – the research team next targeted additional sections of DNA responsible for producing all three proteins – ANP32A, ANP32B and ANP32E – inside lab-grown chicken cells.

In cell cultures in the lab, growth of the virus was successfully blocked in cells with the three gene edits.

The next step will be to try to develop chickens with edits to all three genes. No birds have been produced yet.

The study highlights the importance of responsible gene editing and the need to be alert to the risks of driving viral evolution in unwanted directions if complete resistance is not achieved, experts say.

Bird flu is a major global threat, with a devastating impact in both farmed and wild bird populations. In the UK alone, the current outbreak of H5N1 bird flu has decimated seabird populations and cost the poultry industry more than £100 million in losses.

In rare instances, mutations in the bird flu virus allow it to infect people and cause serious illness. Efforts to control the spread of the disease are urgently needed.

“Bird flu is a great threat to bird populations. Vaccination against the virus poses a number of challenges, with significant practical and cost issues associated with vaccine deployment. Gene-editing offers a promising route towards permanent disease resistance, which could be passed down through generations, protecting poultry and reducing the risks to humans and wild birds. Our work shows that stopping the spread of avian influenza in chickens will need several simultaneous genetic changes.” Professor Mike McGrew, The study’s principal investigator, from the University of Edinburgh’s Roslin Institute

“This work is an exciting collaboration that fuses our expertise in virology with the world-leading genetic capability at the Roslin Institute. Although we haven’t yet got the perfect combination of gene edits to take this approach into the field, the results have told us a lot about how influenza virus functions inside the infected cell and how to slow its replication.” Professor Wendy Barclay, Imperial College London

The research was funded by UKRI-BBSRC, which also provides strategic funding to The Roslin Institute, and was supported by Edinburgh Innovations, the University’s commercialisation service.

Ryan O’Hare’s October 10, 2023 Imperial College London (ICL) press release offers a slightly different perspective on the same work, Note: A link has been removed,

Scientists have successfully used gene editing techniques to limit the spread of bird flu in chickens.

In a UK first, researchers have been able to restrict, but not completely block, the avian influenza virus from infecting the birds by precisely altering a small section of their DNA.

The modified birds showed no signs that the change had any impact on the animals’ health or well-being.

But the researchers say that while the findings are encouraging, further gene edits would be needed to produce chickens which cannot be infected by bird flu.

The study, carried out by researchers from the University of Edinburgh, Imperial College London and the Pirbright Institute, is published in the journal Nature Communications.

Professor Wendy Barclay, Head of the Department of Infectious Disease at Imperial College London, said: “This work is an exciting collaboration that fuses our expertise in virology with the world world-leading genetic capability at the Roslin Institute.

“Although we haven’t yet got the perfect combination of gene edits to take this approach into the field, the results have told us a lot about how influenza virus functions inside the infected cell and how to slow its replication.”

Global Threat

Bird flu is a major global threat, with a devastating impact in both farmed and wild bird populations. In the UK alone, the current outbreak of H5N1 bird flu has decimated seabird populations and cost the poultry industry more than £100 million in losses.

In the latest study, researchers aimed to test whether precise edits to the chicken’s genome could potentially generate birds which are resistant to the virus.

The team bred chickens with small edits to a gene called ANP32A. During an infection, influenza viruses hijack the ANP32A protein to help replicate themselves.

But when the gene-edited birds were exposed to a normal dose of virus (the H9N2 strain of avian influenza), 9 out of 10 birds remained uninfected and there was no spread to other chickens.

When the birds were exposed to an artificially high dose of virus, only half of them became infected. The single gene edit also provided some protection against transmission, with a much lower amount of virus in infected gene-edited birds compared to non-edited birds.

In addition, the edit also helped to limit onward spread of the virus to just one of four non-edited chickens placed in the same incubator. There was no transmission to gene-edited birds.

Triple edits

Analysis revealed that in the edited birds, the virus adapted to enlist the support of two related proteins to replicate – ANP32B and ANP32E.

Following lab tests, the researchers found some of the mutations may enable the virus to utilise the human version of ANP32, but replication remained low in cell cultures from the human airway. The researchers stress that additional genetic changes would be needed for the virus to have the potential to infect and spread effectively in humans.

According to the team, the findings demonstrate that a single gene edit is not robust enough to produce resistant chickens. To prevent the emergence of viruses able to adapt to the single edit, the team next used a triple edit to target additional proteins (ANP32A, ANP32B and ANP32E) in lab-grown chicken cells.

In cell cultures in the lab, growth of the virus was successfully blocked in cells with edits to all three genes. In future, researchers hope to develop chickens with this triple edit, but no birds have been produced at this stage.

According to the researchers, the study highlights the importance of responsible gene editing and the need to be alert to the risks of driving viral evolution in unwanted directions if complete resistance is not achieved, experts say.

Professor Mike McGrew, from the University of Edinburgh’s Roslin Institute and principal investigator of the study, said: “Bird flu is a great threat to bird populations. Vaccination against the virus poses a number of challenges, with significant practical and cost issues associated with vaccine deployment.

“Gene-editing offers a promising route towards permanent disease resistance, which could be passed down through generations, protecting poultry and reducing the risks to humans and wild birds. Our work shows that stopping the spread of avian influenza in chickens will need several simultaneous genetic changes.”

A non-gene-edited chicken (left) pictured next to an ANP32A gene-edited chicken (right). Image credit: Norrie Russell Courtesy: University of Edinburgh

There’s also an October 10, 2023 article by Jon Cohen for Science.org, which gives some idea of how much work it took to get to this point, Note: Links have been removed,

For 3 decades, Helen Sang has tinkered with the genomes of chickens to try to make the birds resistant to the flu viruses that periodically devastate flocks and raise fears of a human pandemic. Now, as an especially virulent strain of avian influenza sweeps through poultry and wild birds around the world, the geneticist at the University of Edinburgh’s Roslin Institute has her first solid success. Using the CRISPR gene editor and recent findings about what makes poultry vulnerable to flu, Sang and colleagues from three other institutions have created chickens that can resist real-life doses of avian flu viruses. “Sticking to it gets you somewhere in the end,” she says.

The result, published today [October 5, 2023] in Nature Communications, is “a long-awaited achievement,” says Jiří Hejnar, a virologist at the Czech Academy of Sciences’s Institute of Molecular Genetics whose group showed in 2020 that CRISPR-edited chickens could resist a cancer-causing virus. But farmers won’t be raising flu-proof chickens anytime soon. The edited birds still became infected when exposed to larger amounts of the flu virus. And the strategy raises a safety concern: chickens edited this way could, in theory, drive the evolution of flu variants better at infecting people. “What this showed is a proof of concept,” says Wendy Barclay, a virologist at Imperial College London who worked on the new study. “But we’re not there yet.”

Here’s a link to and a citation for the paper,

Creating resistance to avian influenza infection through genome editing of the ANP32 gene family by Alewo Idoko-Akoh, Daniel H. Goldhill, Carol M. Sheppard, Dagmara Bialy, Jessica L. Quantrill, Ksenia Sukhova, Jonathan C. Brown, Samuel Richardson, Ciara Campbell, Lorna Taylor, Adrian Sherman, Salik Nazki, Jason S. Long, Michael A. Skinner, Holly Shelton, Helen M. Sang, Wendy S. Barclay & Mike J. McGrew. Nature Communications volume 14, Article number: 6136 (2023) DOI: https://doi.org/10.1038/s41467-023-41476-3 Published: 10 October 2023

This paper is open access.

L’Oréal introduces wearable cosmetic electronic patch (my UV patch)

You don’t (well, I don’t) expect a cosmetics company such as L’Oréal to introduce products at the Consumer Electronics Show (CES) held in Las Vegas (Nevada, US) annually (Jan. 6 – 9, 2016).

A Jan. 6, 2016 article by Zoe Kleinman for BBC (British Broadcasting Corporation) news online explains,

Beauty giant L’Oreal has unveiled a smart skin patch that can track the skin’s exposure to harmful UV rays at the technology show CES in Las Vegas.

The product will be launched in 16 countries including the UK this summer, and will be available for free [emphasis mine].

It contains a photosensitive blue dye, which changes colour when exposed to ultraviolet light.

But the wearer must take a photo of it and then upload it to an app to see the results.

It’s a free app, eh? A cynic might suggest that the company will be getting free data in return.

A Jan. 6, 2016 L’Oréal press release, also on PR Newswire, provides more details (Note: Links have been removed),

Today [Jan. 6, 2016] at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, the first-ever stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. The new technology arrives at a time when sun exposure has become a major health issue, with 90% of nonmelanoma skin cancers being associated with exposure to ultraviolet (UV) radiation from sun* in addition to attributing to skin pigmentation and photoaging.

To address these growing concerns, L’Oréal Group’s leading dermatological skincare brand, La Roche-Posay, is introducing a first-of-its kind stretchable electronic, My UV Patch. The patch is a transparent adhesive that, unlike the rigid wearables currently on the market, stretches and adheres directly to any area of skin that consumers want to monitor. Measuring approximately one square inch in area and 50 micrometers thick – half the thickness of an average strand of hair – the patch contains photosensitive dyes that factor in the baseline skin tone and change colors when exposed to UV rays to indicate varying levels of sun exposure.

Consumers will be able to take a photo of the patch and upload it to the La Roche-Posay My UV Patch mobile app, which analyzes the varying photosensitive dye squares to determine the amount of UV exposure the wearer has received. The My UV Patch mobile app will be available on both iOS and Android, incorporating Near Field Communications (NFC)-enabled technology into the patch-scanning process for Android. My UV Patch is expected to be made available to consumers later this year.

“Connected technologies have the potential to completely disrupt how we monitor the skin’s exposure to various external factors, including UV,” says Guive Balooch, Global Vice President of L’Oréal’s Technology Incubator. “Previous technologies could only tell users the amount of potential sun exposure they were receiving per hour while wearing a rigid, non-stretchable device. The key was to design a sensor that was thin, comfortable and virtually weightless so people would actually want to wear it. We’re excited to be the first beauty company entering the stretchable electronics field and to explore the many potential applications for this technology within our industry and beyond.”

My UV Patch was developed by L’Oréal’s U.S.-based Technology Incubator, a business division dedicated entirely to technological innovation, alongside MC10, Inc., a leading stretchable electronics company using cutting-edge innovation to create the most intelligent, stretchable systems for biometric healthcare analytics. L’Oréal also worked with PCH who design engineered the sensor. The stretchable, peel-and-stick wearable unites L’Oréal Group’s extensive scientific research on the skin and expertise with UV protection with MC10’s strong technological capabilities in physiological sensing and pattern recognition algorithms to measure skin changes over time, and PCH’s 20-year experience in product development, manufacturing and supply chain.

“With My UV Patch, L’Oréal is taking the lead in developing the next generation of smart skincare technology powered by MC10’s unique, stretchable electronics platform, that truly addresses a consumer need,” said Scott Pomerantz, CEO of MC10. “This partnership with L’Oréal marks an exciting new milestone for MC10 and underscores the intersection of tech and beauty and the boundless potential of connected devices within the beauty market.”

*Source: Skin Cancer Foundation 2015

“Together with La Roche-Posay dermatologists like myself, we share a mission to help increase sun safe behavior,” added Alysa Herman, MD.  “La Roche-Posay recently commissioned a global study in 23 countries, which surveyed 19,000 women and men and found a huge gap in consumer behavior: even though 92% were aware that unprotected sun exposure can cause health problems, only 26% of Americans protect themselves all year round, whatever the season. With the new My UV Patch, for the first time, we are leveraging technology to help incite a true behavioral change through real-time knowledge. ”

About L’Oréal

L’Oréal has devoted itself to beauty for over 105 years. With its unique international portfolio of 32 diverse and complementary brands, the Group generated sales amounting to 22.5 billion euros in 2014 and employs 78,600 people worldwide. As the world’s leading beauty company, L’Oréal is present across all distribution networks: mass market, department stores, pharmacies and drugstores, hair salons, travel retail and branded retail.

Research and innovation, and a dedicated research team of 3,700 people, are at the core of L’Oréal’s strategy, working to meet beauty aspirations all over the world and attract one billion new consumers in the years to come. L’Oréal’s new sustainability commitment for 2020 “Sharing Beauty With All” sets out ambitious sustainable development objectives across the Group’s value chain. www.loreal.com

About LA ROCHE-POSAY and ANTHELIOS

Recommended by more than 25,000 dermatologists worldwide, La Roche-Posay offers a unique range of daily skincare developed with dermatologists to meet their standards in efficacy, tolerance and elegant textures for increased compliance. The products, which are developed using a strict formulation charter, include a minimal number of ingredients to reduce side effects and reactivity and are formulated with effective ingredients at optimal concentrations for increased efficacy. Additionally, La Roche-Posay products undergo stringent clinical testing to guarantee efficacy and safety, even on sensitive skin.

About MC10

MC10’s mission is to improve human health through digital healthcare solutions. The company combines its proprietary ultra-thin, stretchable body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 partners with healthcare organizations and researchers to advance medical knowledge and create monitoring and diagnostic solutions for patients and physicians. Backed by a strong syndicate of financial and strategic investors, MC10 has received widespread recognition for its innovative technology, including being named a 2014 CES Innovation in Design Honoree. MC10 is headquartered in Lexington, MA.  Visit MC10 online at www.mc10inc.com.

About PCH

PCH designs custom product solutions for startups and Fortune 500 companies. Whether design engineering and development, manufacturing and fulfilment, distribution or retail, PCH takes on the toughest challenges. If it can be imagined, it can be made. At PCH, we make. www.pchintl.com. Twitter: @PCH_Intl

Ryan O’Hare’s Jan. 6, 2016 article for the UK’s DailyMailOnline provides some additional technology details and offers images of the proposed patch, not reproduced here, (Note: A link has been removed),

The patch and free app, which will be launched in the summer, have been welcomed by experts.

Dr Christopher Rowland Payne, consultant dermatologist to The London Clinic, said: ‘This is an exciting device that will motivate people in a positive way to take control of their sun exposure and will encourage them to know when it is time to leave the sun or to reapply their sunscreen.

‘It is an ingenious way of giving people the information they need. I hope it will also get people talking to each other about safe sun exposure.’

The technology used in the UV patches is based on ‘biostamps’ designed by tech firm MC10.

They were originally designed to help medical teams measure the health of their patients either remotely, or without the need for large expensive machinery.

Motorola were exploring the patches as an alternative to using traditional passwords for security and access to devices.

Getting back to this ‘free app’ business, the data gathered could be used to help the company create future skincare products. If they are planning to harvest your data, there’s nothing inherently wrong with the practice but the company isn’t being as straightforward as it could be. In any event, you may want to take a good at the user agreement and decide for yourself.

Finally, I think it’s time to acknowledge medical writer, Dr. Susan Baxter, (not for the first time and not the last either) as I likely wouldn’t have thought past my general cynicism about data harvesting for a reason, additional to any humanitarian motivations L’Oréal might have, for offering a free mobile app. She doesn’t post on her blog that frequently but it’s always worth taking a look (http://www.susanbaxter.ca/blog-page/) and I recommend this July 30, 2014 post titled, ‘Civil Scientific Discourse RIP’ which focuses on vaccination and anti-vaccination positions. Do not expect a comfortable read.